Already have an account? Sign in.
Wells Fargo Upgrades Glaukos: Hidden Growth Driver Spotted
Wells Fargo raises Glaukos price target to $120, citing Epioxa as underappreciated growth catalyst beyond iDose focus. Stock upgrade to Overweight.
Wells Fargo raises Glaukos price target to $120, citing Epioxa as underappreciated growth catalyst beyond iDose focus. Stock upgrade to Overweight.
Abivax shares fell after Scorpion Capital claimed its ulcerative colitis drug is toxic. The company rejected the report and reaffirmed its Phase 3 data.
CrowdStrike is reportedly in talks to acquire Zscaler in a potential $265 billion cybersecurity deal, one of the largest in the sector.
Canadian Solar shares fell sharply after a report that the solar firm and its Recurrent Energy unit are considering asset sales and a possible Chapter 11 filing.
Be the first to know when deals break, stocks move, or biotech headlines hit.